PARSIPPANY, N.J.--(BUSINESS WIRE)--The Medicines Company (NASDAQ:MDCO) today announced that investigators will present new analyses from high-risk percutaneous coronary intervention (PCI) patient subgroups from the CHAMPION PHOENIX study with its antithrombotic agent, KENGREAL® (cangrelor) for Injection at the 65th Annual Scientific Session of the American College of Cardiology, held April 2-4, in Chicago, IL. CHAMPION PHOENIX included 11,145 patients comparing KENGREAL to oral clopidogrel in patients undergoing PCI and provided the primary evidence of efficacy for the approval of KENGREAL®.
